Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Biol Psychiatry. 2015 Jun 5;79(9):746–754. doi: 10.1016/j.biopsych.2015.05.018

Figure 6. GluN2A reduction rescues PV cell synaptic NMDAR currents at P30.

Figure 6

A and B, Superimposed EPSCs for decay comparison in pyramidal (A) and PV (B) cells from Mecp2-KO/NR2A-Het (KO-Het; red/green), Mecp2-KO (black), and WT (white) mice. Inset A and B: EPSCs from KO-Het (upper) and Mecp2-WT/NR2A-Het (WT-Het; lower) mice in control (black) and ifenprodil-treated (3 µM, gray) conditions. Vertical scale bar 20pA, horizontal 1s. C and E, Decay time constants from pyramidal (C) and PV (E) cells in WT (white), KO (black), KO-Het (red/green bar), and WT-Het (red/green stripe) mice. D and F, Effect of GluN2B antagonist ifenprodil on the NMDAR/AMPAR ratio in pyramidal (D) and PV (F) cells (n=9–18 cells/group; * P < 0.02, ANOVA).